Aura Biosciences Files 8-K, Confirms Emerging Growth Status

Ticker: AURA · Form: 8-K · Filed: Jan 8, 2024 · CIK: 1501796

Aura Biosciences, INC. 8-K Filing Summary
FieldDetail
CompanyAura Biosciences, INC. (AURA)
Form Type8-K
Filed DateJan 8, 2024
Risk Levellow
Pages4
Reading Time4 min
Key Dollar Amounts$0.00001
Sentimentneutral

Complexity: simple

Sentiment: neutral

Topics: regulatory-filing, corporate-governance, accounting-policy

TL;DR

**Aura Biosciences filed a routine 8-K, confirming its emerging growth company status and opting out of extended accounting transition periods.**

AI Summary

Aura Biosciences, Inc. filed an 8-K on January 8, 2024, indicating an 'Other Events' disclosure. This filing, while not detailing specific financial transactions or major corporate changes, confirms Aura Biosciences' status as an 'emerging growth company' and its election not to use the extended transition period for new accounting standards. For investors, this means the company will adopt new accounting standards at the same time as larger, more established companies, potentially offering more transparent and comparable financial reporting sooner.

Why It Matters

This filing confirms Aura Biosciences' regulatory status and accounting policy choices, which can impact how its financial performance is reported and compared to peers. It signals the company's commitment to adopting new accounting standards without delay.

Risk Assessment

Risk Level: low — This 8-K is a routine administrative filing and does not disclose any events that would inherently increase or decrease investment risk.

Analyst Insight

This filing is largely administrative. Smart investors should note the company's choice to forgo the extended accounting transition period, which suggests a preference for earlier compliance with new standards, potentially leading to more timely and comparable financial reporting. No immediate action is warranted based solely on this filing.

Key Players & Entities

Forward-Looking Statements

FAQ

What is the primary purpose of this 8-K filing by Aura Biosciences, Inc.?

The primary purpose of this 8-K filing by Aura Biosciences, Inc. is to report 'Other Events' and 'Financial Statements and Exhibits' as of January 8, 2024. It also confirms the company's status as an 'emerging growth company' and indicates its election regarding accounting standards.

What is Aura Biosciences, Inc.'s status regarding 'emerging growth company' as defined by the SEC?

Aura Biosciences, Inc. indicates by check mark that it is an 'emerging growth company' as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Has Aura Biosciences, Inc. elected to use the extended transition period for new financial accounting standards?

No, Aura Biosciences, Inc. has indicated by check mark that it has elected *not* to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

What is the business address and phone number of Aura Biosciences, Inc. as stated in the filing?

The business address of Aura Biosciences, Inc. is 80 Guest Street, Boston, MA 02135, and its business phone number is (617) 500-8864.

What is the Central Index Key (CIK) for Aura Biosciences, Inc.?

The Central Index Key (CIK) for Aura Biosciences, Inc. is 0001501796.

Filing Stats: 1,057 words · 4 min read · ~4 pages · Grade level 14.7 · Accepted 2024-01-08 07:31:02

Key Financial Figures

Filing Documents

01

Item 8.01. Other Events. Aura Biosciences, Inc. (the "Company") will be conducting meetings with investors attending the 42 nd Annual J.P. Morgan Healthcare Conference in San Francisco beginning on January 8, 2024. The Company updated its corporate presentation for use in these meetings. A copy of the corporate presentation is filed as Exhibit 99.1 for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act").

Forward Looking Statements

Forward Looking Statements Any forward-looking statements are neither promises nor guarantees, and investors should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are be

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Corporate presentation of the Company 104 Cover Page Interactive Data (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: January 8, 2024 AURA BIOSCIENCES, INC. By: /s/ Julie Feder Julie Feder Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing